Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.
about
The 2007 Rift Valley fever outbreak in SudanStatistical modeling of the abundance of vectors of West African Rift Valley fever in Barkédji, SenegalDevelopment of an improved polykaryon-based influenza virus rescue system.Synthetic biology: mapping the scientific landscape.Molecular biology of rift valley Fever virusRift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and preventionTissue tropism and target cells of NSs-deleted rift valley fever virus in live immunodeficient mice.Predicting the mosquito species and vertebrate species involved in the theoretical transmission of Rift Valley fever virus in the United StatesRift valley fever: recent insights into pathogenesis and preventionInfection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infectionThe Rift Valley Fever virus protein NSm and putative cellular protein interactionsRift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.Towards a safe, effective vaccine for Rift Valley fever virusA single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs.Advances in Rift Valley fever research: insights for disease preventionCreation of a nonspreading Rift Valley fever virusTranslational research in infectious disease: current paradigms and challenges ahead.Curcumin inhibits Rift Valley fever virus replication in human cells.Vector competence of Aedes vexans (Meigen), Culex poicilipes (Theobald) and Cx. quinquefasciatus Say from Senegal for West and East African lineages of Rift Valley fever virusA genome-wide RNAi screen reveals that mRNA decapping restricts bunyaviral replication by limiting the pools of Dcp2-accessible targets for cap-snatchingIFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.Vaccines for viral hemorrhagic fevers--progress and shortcomingsConstruction and characterisation of a complete reverse genetics system of dengue virus type 3.Creation of a recombinant Rift Valley fever virus with a two-segmented genome.Characterization of wild-type and alternate transcription termination signals in the Rift Valley fever virus genomeA glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep.Virus-like particle-based countermeasures against Rift Valley fever virus.Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome.The nonstructural protein NSs induces a variable antibody response in domestic ruminants naturally infected with Rift Valley fever virus.Retrovirus-Based Surrogate Systems for BSL-2 High-Throughput Screening of Antivirals Targeting BSL-3/4 Hemorrhagic Fever-Causing Viruses.Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound.
P2860
Q27026883-E019F593-771E-483B-9B34-2D328436A7DFQ28650806-8E630EC1-1EAD-4E63-AACE-B4ECCEC7ECF7Q30533592-6C5B34F7-A11E-42D3-91D0-172617E4CC48Q31059198-328E90BF-838E-41C2-AA03-F5EDF2CE0478Q33886954-25A2D2FB-FD0D-4A98-8164-4A4DE7D85735Q33960690-A4D48BC1-EFCC-4B6D-AA52-81CDA29D415DQ34097995-66311BFF-DE62-4E16-81C0-55A170A6ECD3Q34165833-2B8E4C4D-7924-4D94-BBF5-050F05BD0742Q34174444-6C41689C-86DC-4BD8-B60E-52D47D78C159Q34260234-9FFDDCF8-3FF6-4702-B9E5-EF6B0FC19C6BQ34354086-365A97D2-3E0D-4368-9C0F-5BD493ED6C4EQ34475358-D456B696-48EB-4B97-9DC1-FDC58E5958D4Q34529382-22F36D89-35E7-4AA2-8CAB-6C1232A8BED2Q34677989-17E3CCA9-5733-43D9-9EE3-F3D92C052893Q35027744-987CC110-C538-434D-B4A4-1F8DF99DCC2FQ35077969-C2892A6A-578E-4A42-B903-A54929664FBAQ35531617-FD8B57F3-232E-44DC-81C0-A1973ACF7288Q35992621-20A69E22-F7B3-4D9F-A448-D88ED78714A0Q36286082-7BDE686A-5502-44F1-BB3C-9162B288C195Q36599998-94C365F9-BED9-48F2-B099-C6AA9A59B441Q37019225-DB772C75-0620-4B6A-B776-BC2969F11DE2Q37036679-3D76A036-2D6B-4F2E-9128-94D5618CBF5AQ37096221-8E5B1F10-4D1C-4EAC-BBAB-67CB2264C0B8Q37734118-EDE89A51-1BCD-45C8-8253-E334BF6433CFQ38748778-A7FFBF61-8350-4D20-AC74-729C1B3057A2Q38960700-58CA563E-E000-4B40-850E-DBCA74732029Q40186455-49B9457D-06F1-43E4-9B4D-C1688EF44003Q40254473-36E34170-E5ED-4605-B072-E7AE321A8CCCQ40277454-0B6F3884-732C-449D-95F6-10770494DCD2Q40306367-DA8C54B2-E483-4687-9425-AB536F56E30EQ41922316-F6ED1B64-DD53-4754-9D48-8C9108425046Q47547438-AC8DF193-7B52-404C-9F97-D43F5D0C2B5A
P2860
Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Reverse genetics technology fo ...... of therapeutics and vaccines.
@ast
Reverse genetics technology fo ...... of therapeutics and vaccines.
@en
Reverse genetics technology fo ...... of therapeutics and vaccines.
@nl
type
label
Reverse genetics technology fo ...... of therapeutics and vaccines.
@ast
Reverse genetics technology fo ...... of therapeutics and vaccines.
@en
Reverse genetics technology fo ...... of therapeutics and vaccines.
@nl
prefLabel
Reverse genetics technology fo ...... of therapeutics and vaccines.
@ast
Reverse genetics technology fo ...... of therapeutics and vaccines.
@en
Reverse genetics technology fo ...... of therapeutics and vaccines.
@nl
P2860
P1433
P1476
Reverse genetics technology fo ...... of therapeutics and vaccines.
@en
P2093
Michele Bouloy
Ramon Flick
P2860
P304
P356
10.1016/J.ANTIVIRAL.2009.08.002
P577
2009-08-12T00:00:00Z